Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC

Amin H. Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances A. Shepherd, Elio Adib, Justin M. Cheung, W. Marston Linehan, Yufei Liu, Steven H. Lin, Kaushal Parikh, Arthi Sridhar, Purnima Shakya, Thomas J. Dilling, David Kaldas, Jhanelle E. Gray, Anastasiya Lobachov, Jair Bar, H Lüders, Christian Grohé, Shruti Gupta, Ticiana Leal, Bailey G. Fitzgerald, Fionnuala Crowley, Yu Fujiwara, Thomas U. Marron, M. Wilgucki, Joshua E. Reuss, Luxi Chen, K. Nathan Sankar, Jacqueline V. Aredo, Joel W. Neal, Heather A. Wakelee, Rohit Thummalapalli, Helena A. Yu, Ryan Whitaker, Ana I. Velázquez, Meera Vimala Ragavan, Alessio Cortellini, David J. Kwiatkowski, Abdul Rafeh Naqash, Sarah B. Goldberg, So Yeon Kim